Technical Data Sheet

Purified Mouse Anti-TFIIB

Product Information

 $\begin{tabular}{llll} \mbox{Material Number:} & \mbox{610463} \\ \mbox{Size:} & \mbox{150 μg} \\ \mbox{Concentration:} & \mbox{250 $\mu g/ml$} \\ \mbox{Clone:} & \mbox{24/TFIIB} \\ \end{tabular}$

Immunogen: Human TFIIB aa. 2-155

 Isotype:
 Mouse IgG2a

 Reactivity:
 QC Testing: Human

Tested in Development: Dog, Frog, Mouse, Rat

Target MW: 38 kD


Storage Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium

azide.


Description

TFIIB is a ubiquitous factor required for transcription initiation by RNA polymerase II. Studies suggest that TFIIB serves as a bridge between the "TATA"-binding factor (TFIID) and RNA polymerase II during pre-initiation complex assembly and that TFIIB can be a target of acidic activators. An essential component of the machinery that transcribes protein-coding genes, the three-dimensional structure of the human TFIIB appears to consist of two direct repeats that adopt similar alpha-helical folds, conferring pseudo-twofold symmetry. An extensive, central basic surface, including an amphipathic alpha helix, is critical to the function of TFIIB as a bridge between the TBP-promoter complex and transcription factors. TFIIB has a calculated molecular weight of 33 kD and has been reported to be observed to migrate between 33-40 kD.

This antibody is routinely tested by western blot analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.



Western blot analysis of TFIIB on a A431 cell lysate (Human epithelial carcinoma; ATCC CRL-1555). Lane 1: 1:250, lane 2: 1:500, lane 3: 1:1000 dilution of the anti-TFIIB antibody.



Immunofluorescence staining of HeLa cells (Human cervical epitheloid carcinoma; ATCC CCL-2.2).

Preparation and Storage

Store undiluted at -20° C.

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

BD Biosciences

bdbiosciences.com

United States Canada Europe Japan Asia Pacific Latin America/Caribbear 877.232.8995 888.259.0187 32.53.720.550 0120.8555.90 65.6861.0633 55.11.5185.9995 For country-specific contact information, visit bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2006 BD



Application Notes

Application

- 11		
Western blot	Routinely Tested	
Immunofluorescence	Tested During Development	
Immunoprecipitation	Tested During Development	
Immunohistochemistry	Not Recommended	

Recommended Assay Procedure:

Western blot: Please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western Blotting.shtml

Suggested Companion Products

Catalog Number	Name	Size	Clone	
611447	A431 Cell Lysate	500 μg	(none)	_
554002	HRP Goat Anti-Mouse Igs	1.0 ml	(none)	
554001	FITC Goat Anti-Mouse Igs	0.5 mg	Polyclonal	

Product Notices

- 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- 2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
- 3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- 4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

References

Bagby S, Kim S, Maldonado E, Tong KI, Reinberg D, Ikura M. Solution structure of the C-terminal core domain of human TFIIB: similarity to cyclin A and interaction with TATA-binding protein. *Cell.* 1995; 82(5):857-867.(Biology)

Lamberti C, Lin KM, Yamamoto Y, et al. Regulation of beta-catenin function by the IkappaB kinases. *J Biol Chem.* 2001; 276(45):42276-42286.(Biology: Immunofluorescence)

Malik S, Hisatake K, Sumimoto H, Horikoshi M, Roeder RG. Sequence of general transcription factor TFIIB and relationships to other initiation factors. *Proc Natl Acad Sci U S A.* 1991; 88(21):9553-9557.(Biology)

Pellizzoni L, Charroux B, Rappsilber J, Mann M, Dreyfuss G. A functional interaction between the survival motor neuron complex and RNA polymerase II. *J Cell Biol.* 2001; 152(1):75-85.(Biology: Western blot)

610463 Rev. 1 Page 2 of 2